Clinical Trial

An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC

Study acronym: SCHBCC-N0117
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a prospective, open-label, phase III, randomized controlled clinical trial. It is planned to screen patients with inoperable locally advanced or metastatic triple-negative breast cancer of the LAR subtype. A total of 180 patients are planned to be enrolled.
Trial Details
NCT Number NCT07760844
Lead Sponsor Fudan University
Conditions Breast Cancer, Triple Negative Breast Cancer (TNBC)
Enrollment 180 participants
Start Date 2026-10-01
Primary Completion 2028-09-30 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-12